drug

Ethyl-eicosapentaenoic acid (EPA)

as of 2026-07-01

Add to landscape Monitor this Compare this Ask about this

at a glance

small molecule

Pre-approval / investigational in the US

Developed by University Hospital, Aker

1 trials in the graph

Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality

small molecule

Indications

Investigational (via trials)

Schizophrenia Schizophreniform Disorders Hypertriglyceridemia Schizophrenia Hallucinations Psychotic Disorders Delusions Psychotic Disorders Schizoaffective Disorder

Trials

Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants

NCT00419146Phase 2, Phase 3Completed

KOLs & investigators

Håvard Bentsen, MD PhD

Odd Lingjærde, MD PhD

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

developer

University Hospital, Aker

company

trial

Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants

PHASE2, PHASE3

trial

indication

Schizophrenia

indication

Schizophreniform Disorders

indication

Hypertriglyceridemia

indication

Schizophrenia

indication

KOL

Håvard Bentsen, MD PhD

KOL score —

person

Odd Lingjærde, MD PhD

KOL score —

person